The global peripheral vascular devices market, valued at USD 4.7 billion in 2022, is projected to expand at a robust CAGR of 6.6%, reaching USD 8.9 billion by 2032, according to Future Market Insights ...

Analysts have set 12-month price targets for Merit Medical Systems, revealing an average target of $114.12, a high estimate ...

R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce ...

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

Semaglutide, more commonly known as Ozempic, can do more than help with weight loss. A new clinical trial shows it helps ...

UK: A Mendelian randomization study published in the Journal of the American College of Cardiology identified elevated ...

R3 Vascular Inc. announced that the first patient was enrolled in the company’s ELITE-BTK pivotal trial evaluating its Magn ...

• Antibiotics seem to reduce surgical site infections in people undergoing aortic or aortoiliac surgery. • Other interventions assessed appear to make little or no difference in reducing the incidence ...

The latest data from the DWP shows that, as of August last year, 1.7 million people across Great Britain were receiving ...

Efemoral Medical announced the presentation of long-term results from the initial 20 patients enrolled across four sites in ...

R3 Vascular announced that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting ...